Aptinyx (APTX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
May 12, 2022 4:05 PM EDTCurrent cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies
Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022
Data readout from exploratory Phase 2 study of NYX-458 in cognitive impairment expected in late 2022 or 1Q 2023
Data readout from Phase 2b study of NYX-783 50 mg in PTSD expected in 2H 2023
Conference call today at 5:00 p.m. ET
EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq:... More



